Company intelligence / Profile preview

ECS-Progastrin SA

Lausanne, Vaud, Switzerlandpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

ECS-Progastrin SA has developed a robust and reliable ELISA-based blood test for detecting circulating hPG80 (progastrin), a biomarker overexpressed in various cancers. Their technology enables early cancer diagnosis and monitoring of treatment efficacy. The company is also developing anti-hPG80 therapeutic antibodies with potential applications across multiple tumor types. Clinical studies have demonstrated the utility of their diagnostic kits in stratifying patients and predicting outcomes in several cancers.

Therapeutic areas: Oncology
Modalities: Diagnostic assays (ELISA-based blood tests)Therapeutic antibodies targeting hPG80/progastrin
Industry: Biotech

Beyond the preview

Go deeper on ECS-Progastrin SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECS-Progastrin SA.

Explore the full profile